Please assess the completion status of the following clinical trial:

Trial Title: Adding Phosphorus to Osteoporosis Drug Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bone mineral density (BMD) T-score less than -1.0~* One or more vertebral fractures~* Serum creatinine less than 1.3 mg/dL~* Serum phosphorus less than 3.6 mg/dL~* Daily phosphorus intake below NHANES-III median~* Body mass index (BMI) less than 30 kg/m2~Exclusion Criteria:~* Paget's disease or history of osteosarcoma~* Systemic corticosteroid therapy~* Hyperparathyroidism~* Recent history of kidney stone~* Anticonvulsant therapy known to alter vitamin D metabolism~* Radiation therapy to bone

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Calcium Phosphate Treatment Group (Type: ACTIVE_COMPARATOR): Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
- Calcium Carbonate Treatment Group (Type: ACTIVE_COMPARATOR): Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.

Based on this trial design, predict the completion outcome and termination type (if applicable).